Gilead Sciences (NASDAQ:GILD) Price Target Raised to $103.00 at Royal Bank Of Canada

Gilead Sciences (NASDAQ:GILD) had its price objective increased by Royal Bank Of Canada from $100.00 to $103.00 in a report issued on Tuesday,MarketScreener reports. The brokerage currently has a sector perform rating on the biopharmaceutical company’s stock.

GILD has been the subject of several other reports. Citigroup boosted their target price on Gilead Sciences from $135.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. TD Cowen lifted their price objective on shares of Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Mizuho boosted their price objective on shares of Gilead Sciences from $131.00 to $140.00 and gave the company an “outperform” rating in a report on Friday, November 21st. Morgan Stanley cut their target price on shares of Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating on the stock in a report on Tuesday, January 13th. Finally, Scotiabank began coverage on shares of Gilead Sciences in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $133.28.

Gilead Sciences Price Performance

Shares of GILD stock opened at $124.14 on Tuesday. The firm’s 50 day moving average price is $123.53 and its two-hundred day moving average price is $118.29. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. Gilead Sciences has a 52-week low of $91.84 and a 52-week high of $128.70. The stock has a market cap of $154.02 billion, a PE ratio of 19.25, a PEG ratio of 0.66 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. During the same quarter in the prior year, the business posted $2.02 EPS. The firm’s quarterly revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, analysts forecast that Gilead Sciences will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Investors of record on Monday, December 15th were given a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend was Monday, December 15th. Gilead Sciences’s payout ratio is currently 48.99%.

Insider Activity

In other news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the completion of the transaction, the insider directly owned 107,193 shares of the company’s stock, valued at $13,491,310.98. This represents a 20.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total value of $1,193,900.00. Following the completion of the sale, the chief executive officer directly owned 581,203 shares in the company, valued at approximately $69,389,826.17. This represents a 1.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 136,757 shares of company stock worth $16,951,612. 0.27% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Gilead Sciences

Large investors have recently bought and sold shares of the company. Brighton Jones LLC grew its position in Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 2,450 shares in the last quarter. Bison Wealth LLC bought a new position in shares of Gilead Sciences in the 4th quarter valued at about $215,000. Sivia Capital Partners LLC grew its holdings in shares of Gilead Sciences by 16.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after acquiring an additional 602 shares in the last quarter. Silver Oak Securities Incorporated acquired a new stake in shares of Gilead Sciences in the second quarter valued at about $415,000. Finally, Foster Group Inc. bought a new stake in Gilead Sciences during the second quarter worth about $207,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.